DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Polatuzumab Vedotin in First-Line DLBCL Treatment: Phase 3 POLARIX Trial Analysis in Asian Subpopulation Feb 24, 2023
Lung Cancer,Popular,SCLC (Small Cell Lung Cancer) Clinical Outcomes with High-Dose Once-Daily Thoracic Radiotherapy Feb 24, 2023
Bladder Cancer,Genitourinary Cancer,Popular PURE-01 Trial: Neoadjuvant Pembrolizumab and Radical Cystectomy in MIBC Patients Feb 24, 2023
Colorectal Cancer,Gastrointestinal Cancer Phase I/II Study of Selpercatinib in RET Fusion-Positive NSCLC Patients with CNS Involvement Feb 24, 2023
Gastrointestinal Cancer,Pancreatic Cancer Nab-Paclitaxel and Gemcitabine vs. Gemcitabine Monotherapy in Resected Pancreatic Ductal Adenocarcinoma: Phase III Results Feb 24, 2023
Gastric Cancer,Gastrointestinal Cancer Futibatinib in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Phase 1/2 Study Feb 24, 2023
Esophageal Cancer,Gastrointestinal Cancer Patient-Reported Outcomes from Mobocertinib Phase 1/2 Study in EGFR+ Metastatic NSCLC: EXCLAIM Extension Cohort Results Feb 24, 2023
Breast Cancer,HER2+ Comparing Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Metastatic Breast Cancer Phase 3 Trial Feb 24, 2023
